Skip to main content

Table 3 Consent to treatment

From: Retrospective agreement and consent to neurocritical care is influenced by functional outcome

  Ischemia ICH SAH Meningoencephalitis Epilepsy GBS/MG Neurodeg./
Enceph.
Cerebral
neoplasm
Intox.
mRS 0-1 (n, %) 24/25 (96.0) 28/30 (93.3) 9/9 (100.0) 23/24 (95.87) 44/49 (89.8) 10/10 (100.0) 1/1 (100.0) 0/0 7/7 (100.0)
mRS 2-3 (n, %) 35/44 (79.9) 13/17 (76.5) 1/2 (50.0) 5/7 (71.4) 1/4 (25.0) 7/9 (77.8) 2/3 (66.7) 2/2 (100.0) 7/8 (87.5)
mRS 4-5 (n, %) 4/68 (5.8) 3/41 (7.3) 4/8 (50.0) 5/9 (55.6) 8/19 (42.1) 1/4 (25.0) 2/6 (33.3) 1/2 (50.0) 2/4 (50.0)
mRS 6
(n, %)
35/104 (33.7) 32/117 (27.4) 9/18 (50.0) 5/7 (71.4) 9/14 (64.3) 1/1 (100.0) 6/10 (60.0) 11/15 (73.3) 4/6 (66.7)
  1. Consent to treatment (%) according to diagnosis and separated by functional outcome, that is, the proportion of patients with a specific disease and with a specific outcome who retrospectively agreed and consented to neurocritical care.
  2. ICH, Intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; neurodeg, neurodegenerative disease; Enceph, encephalopathy; Intox, intoxication; n, number; mRS, modified Rankin Scale.